In CML patients during IM treatment, enhanced Separase proteolytic activity in bcr-abl-positive stem and progenitor cells with residual BCR-ABL protein expression may promote tumor heterogeneity, clonal evolution and development of resistance. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.